Clinical Edge Journal Scan

Hyperglycemia and low BMI increase the risk for gastric cancer


 

Key clinical point: Low body mass index (BMI) increased the risk for gastric cancer in men and women, whereas high fasting glucose levels slightly increased the risk in women but not in men.

Major finding: Low BMI (<18.5 kg/m 2) increased the risk for gastric cancer in both men (adjusted odds ratio [aOR] 1.39; P < .001) and women (aOR 1.48; P < .001). High fasting glucose levels (≥126 mg/dL) slightly elevated gastric cancer risk in women (aOR 1.19; P < .001) but not in men.

Study details: This prospective, population-based cohort study included 5174 million individuals (men, 43.1%) who underwent national gastric cancer screening and were followed up for 9 years.

Disclosures: This study was funded by the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea; and others. The authors declared no conflicts of interest.

Source: Nam SY et al. Sex-specific effect of body mass index and fasting glucose on gastric cancer risk and all causes mortality; a cohort study of 5.17 million. Int J Obes. 2022 (Jun 10). Doi: 10.1038/s41366-022-01161-9

Recommended Reading

FOLFIRI-bevacizumab tops FOLFIRI-aflibercept in treating metastatic CRC after FOLFOX-bevacizumab failure
MDedge Hematology and Oncology
Efficacy of colonoscopy for preventing CRC remains unaffected by location
MDedge Hematology and Oncology
Cytoreductive surgery + hyperthermic intraperitoneal chemotherapy confers survival benefit in CRC peritoneal metastasis
MDedge Hematology and Oncology
CRC: Colonoscopy offers a survival benefit over fecal immunochemical test
MDedge Hematology and Oncology
Cardiovascular disease: The leading cause of noncancer death in CRC
MDedge Hematology and Oncology
Hepatic arterial infusion-chemotherapy with FOLFIRINOX: A feasible treatment option for metastatic CRC
MDedge Hematology and Oncology
Beta adrenergic blockade improves the prognosis of patients with CRC
MDedge Hematology and Oncology
Advanced gastric cancer: Efficacy of anti-PD-1 antibodies plus multikinase inhibitors unaffected by liver metastasis
MDedge Hematology and Oncology
Chemoradiotherapy improves survival in resectable gastric cancer
MDedge Hematology and Oncology
Better survival in patients with MSI-high vs MSS gastric cancer despite worse chemotherapy response
MDedge Hematology and Oncology